Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Bristol Myers Squibb Co.

Related BMY
Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug
Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend
The Stocks Already in Correction Mode (Fox Business)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Bristol Myers Squibb Co. (NYSE: BMY), and slightly raised its price target from $38.00 to $39.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Bristol Myers Squibb Co. closed on Tuesday at $34.22.

Latest Ratings for BMY

DateFirmActionFromTo
Aug 2014Deutsche BankInitiates Coverage onHold
Aug 2014JefferiesMaintainsHold
Jul 2014JefferiesMaintainsHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters